论文部分内容阅读
目的研究利巴韦林缓释微丸在家犬体内的药物动力学、相对生物利用度及体内外相关性。方法应用HPLC法,以市售普通片为对照,测定利巴韦林缓释微丸口服给药后家犬血浆中的药物浓度,经3P97程序拟合血药浓度-时间数据得出相应的参数,并计算相对生物利用度。结果利巴韦林缓释微丸和普通片口服后tmax分别为(3.59±0.96)h和(0.38±0.22)h,cmax分别为(3.23±0.97)mg·L-1和(6.62±2.10)mg·L-1,AUC0-t分别为(39.69±6.77)·mg·hL-1和(38.27±8.87)mg·h·L-1,相对生物利用度为103.7%,其体内吸收与体外释药具有显著的相关性。结论利巴韦林缓释微丸具有明显的缓释特征。
Objective To study the pharmacokinetics, relative bioavailability and in vitro and in vivo correlation of ribavirin sustained-release pellets in dogs. Methods The HPLC method was used to determine the drug concentration of ribavirin sustained-release pellets in the plasma of dogs after the oral administration of ribavirin sustained-release pellets. The corresponding parameters were obtained from the blood concentration-time data of 3P97 program , And calculate the relative bioavailability. Results The tmax values were (3.59 ± 0.96) h and (0.38 ± 0.22) h, respectively, and the values of cmax were (3.23 ± 0.97) mg · L-1 and (6.62 ± 2.10) mg respectively after oral administration of ribavirin sustained- · The relative bioavailability of L-1 and AUC0-t was (39.69 ± 6.77) mg · hL-1 and (38.27 ± 8.87) mg · h · L-1, respectively. The relative bioavailability was 103.7% There is a significant correlation. Conclusion ribavirin sustained-release pellets have obvious sustained-release characteristics.